SOAM
APGE icon

SBI Okasan Asset Management’s Apogee Therapeutics APGE Stock Holding History

SBI Okasan Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$942K Hold
7,100
– – 0.03% 138
2026
Q1 		$559K Buy
+7,100
New +$516K 0.02% 184

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

SBI Okasan Asset Management's APGE Position: Q2 2026 in Review

SBI Okasan Asset Management held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 7,100 shares worth $942K. The position accounts for 0.03% of the portfolio, ranked #138.

SBI Okasan Asset Management first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • SBI Okasan Asset Management held 7,100 shares of Apogee Therapeutics worth $942K as of Q2 2026.
  • SBI Okasan Asset Management left its Apogee Therapeutics share count unchanged in Q2 2026.
  • Apogee Therapeutics made up 0.03% of SBI Okasan Asset Management's portfolio in Q2 2026, its #138 holding.
  • SBI Okasan Asset Management first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on SBI Okasan Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.